ZB021 / InnoCare, Zenas BioPharma - LARVOL DELTA

Subject to Investigational New Drug (IND) clearance, Zenas expects to initiate Phase 1 clinical development for ZB021, a potentially best-in-class oral IL-17AA/AF inhibitor, in 2026 (GlobeNewswire) - "Pending Phase 1 data, Zenas expects to advance development of ZB021 for rheumatic and/or dermatologic diseases."

New P1 trial • Dermatology • Rheumatology

In Investigational New Drug (IND) enabling studies: Zenas expects to submit an IND and initiate Phase 1 clinical development in 2026. Pending Phase 1 data, Zenas expects to advance development of ZB021 for rheumatic and/or dermatologic diseases. (GlobeNewswire)

IND • New P1 trial • Dermatology • Rheumatology

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) - "Zenas also secured rights to a novel, oral, IL-17AA/AF inhibitor, and an oral, brain-penetrant, TYK2 inhibitor....Under the license agreement, Zenas will pay InnoCare upfront and near-term milestone payments of up to $100 million in cash, including milestone achievements expected in 2026, and up to 7,000,000 shares of Zenas common stock, including shares issuable upon a milestone expected to be achieved in early 2026."

Licensing / partnership • Multiple Sclerosis

A novel oral IL-17AA/AF inhibitor, and an oral, brain-penetrant, TYK2 inhibitor, expected to begin Phase 1 clinical trials in 2026 (GlobeNewswire)

New P1 trial • Immunology